BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19773200)

  • 1. MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma.
    Kan T; Meltzer SJ
    Curr Opin Pharmacol; 2009 Dec; 9(6):727-32. PubMed ID: 19773200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim.
    Kan T; Sato F; Ito T; Matsumura N; David S; Cheng Y; Agarwal R; Paun BC; Jin Z; Olaru AV; Selaru FM; Hamilton JP; Yang J; Abraham JM; Mori Y; Meltzer SJ
    Gastroenterology; 2009 May; 136(5):1689-700. PubMed ID: 19422085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of MicroRNAs in the progression of barrett esophagus to adenocarcinoma in a long-term follow-up study.
    Revilla-Nuin B; Parrilla P; Lozano JJ; de Haro LF; Ortiz A; Martínez C; Munitiz V; de Angulo DR; Bermejo J; Molina J; Cayuela ML; Yélamos J
    Ann Surg; 2013 May; 257(5):886-93. PubMed ID: 23059500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
    Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
    Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.
    Craig MP; Rajakaruna S; Paliy O; Sajjad M; Madhavan S; Reddy N; Zhang J; Bottomley M; Agrawal S; Kadakia MP
    Clin Transl Gastroenterol; 2020 Jan; 11(1):e00125. PubMed ID: 31934893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma.
    Fang Y; Chen X; Bajpai M; Verma A; Das KM; Souza RF; Garman KS; Donohoe CL; O'Farrell NJ; Reynolds JV; Dvorak K
    Ann N Y Acad Sci; 2013 Oct; 1300():187-199. PubMed ID: 24117642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference.
    Zhou Z; Xia Y; Bandla S; Zakharov V; Wu S; Peters J; Godfrey TE; Sun J
    Hum Pathol; 2014 Aug; 45(8):1744-51. PubMed ID: 24951052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
    Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
    Oncogene; 2006 May; 25(21):3084-92. PubMed ID: 16407829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.
    Streppel MM; Pai S; Campbell NR; Hu C; Yabuuchi S; Canto MI; Wang JS; Montgomery EA; Maitra A
    Clin Cancer Res; 2013 Aug; 19(15):4067-78. PubMed ID: 23757351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
    Maru DM; Singh RR; Hannah C; Albarracin CT; Li YX; Abraham R; Romans AM; Yao H; Luthra MG; Anandasabapathy S; Swisher SG; Hofstetter WL; Rashid A; Luthra R
    Am J Pathol; 2009 May; 174(5):1940-8. PubMed ID: 19342367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.
    Yang H; Gu J; Wang KK; Zhang W; Xing J; Chen Z; Ajani JA; Wu X
    Clin Cancer Res; 2009 Sep; 15(18):5744-52. PubMed ID: 19737949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and clinical implementation of biomarkers for Barrett's esophagus.
    Varghese S; Lao-Sirieix P; Fitzgerald RC
    Gastroenterology; 2012 Mar; 142(3):435-441.e2. PubMed ID: 22266150
    [No Abstract]   [Full Text] [Related]  

  • 18. Myo9B is associated with an increased risk of Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; Van Zoest KP; Moons LM; Pot RG; Siersema PD; Kuipers EJ; Kusters JG
    Scand J Gastroenterol; 2012 Dec; 47(12):1422-8. PubMed ID: 22954106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biology of Barrett's esophagus and esophageal adenocarcinoma.
    Wang DH; Souza RF
    Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):25-38. PubMed ID: 21112495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.
    Fassan M; Pizzi M; Battaglia G; Giacomelli L; Parente P; Bocus P; Ancona E; Rugge M
    J Clin Pathol; 2010 Aug; 63(8):692-6. PubMed ID: 20702469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.